Discriminative Stimulus Effects of Substituted Tryptamines in Rats.

Novel synthetic compounds have been available for decades as quasi-legal alternatives to controlled substances. The hallucinogen-like effects of eight novel substituted tryptamines were evaluated to determine their potential abuse liability. Male Sprague-Dawley rats were trained to discriminate 2,5-dimethoxy-4-methylamphetamine (DOM, 0.5 mg/kg, i.p., 30 min) from saline. 4-Acetoxy-N,N-diethyltryptamine (4-AcO-DET), 4-hydroxy-N-methyl-N-ethyltryptamine (4-OH-MET), 4-hydroxy-N,N-diethyltryptamine (4-OH-DET), 4-acetoxy-N-methyl-N-isopropyltryptamine (4-AcO-MiPT), 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT), 4-hydroxy-N,N-dimethyltryptamine (4-OH-DMT, psilocin), 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT), 4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT), and 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT) were tested for their ability to substitute for the discriminative stimulus effects of DOM. All test compounds fully substituted for DOM with potencies less than or equal to that of DOM. 4-OH-MET, 4-OH-DET, 4-OH-DMT, and 4-AcO-DMT decreased response rate at doses that fully substituted. Because the test compounds produced DOM-like discriminative stimulus effects, they may have similar abuse liability as DOM. 4-Acetoxy substituted compounds were less potent than 4-hydroxy substituted compounds, and the N,N-diisopropyl compounds were less potent than the dimethyl, diethyl, N-methyl-N-ethyl, and N-methyl-N-isopropyl compounds.

[1]  G. Knudsen,et al.  Plasma psilocin critically determines behavioral and neurobiological effects of psilocybin , 2020, Neuropsychopharmacology.

[2]  Matthew W. Johnson,et al.  Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan , 2020, Psychopharmacology.

[3]  J. Wallach,et al.  Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species , 2020, Neuropharmacology.

[4]  R. Stevenson,et al.  A systematic study of microdosing psychedelics , 2018, PloS one.

[5]  C. Svarer,et al.  Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels , 2019, Neuropsychopharmacology.

[6]  Haden Geiger,et al.  DARK Classics in Chemical Neuroscience: Psilocybin. , 2018, ACS chemical neuroscience.

[7]  Mark I. Johnson,et al.  Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role? , 2018, Pain management.

[8]  M. Farré,et al.  Something New about Something Old: A 10-Year Follow-Up on Classical and New Psychoactive Tryptamines and Results of Analysis , 2017, Journal of psychoactive drugs.

[9]  D. van der Kooy,et al.  A single administration of the hallucinogen, 4‐acetoxy‐dimethyltryptamine, prevents the shift to a drug‐dependent state and the expression of withdrawal aversions in rodents , 2017, The European journal of neuroscience.

[10]  Matthew W. Johnson,et al.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial , 2016, Journal of psychopharmacology.

[11]  M. Barratt,et al.  Correlates of new psychoactive substance use among a self-selected sample of nightclub attendees in the United States. , 2016, The American journal on addictions.

[12]  M. Liechti,et al.  Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens , 2016, European Neuropsychopharmacology.

[13]  Matthew W. Johnson,et al.  Classic hallucinogens in the treatment of addictions , 2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[14]  Iain M McIntyre,et al.  A Fatality Related to Two Novel Hallucinogenic Compounds: 4-Methoxyphencyclidine and 4-Hydroxy-N-methyl-N-ethyltryptamine. , 2015, Journal of analytical toxicology.

[15]  V. Andreu,et al.  Simultaneous determination of traditional and emerging illicit drugs in sediments, sludges and particulate matter. , 2015, Journal of chromatography. A.

[16]  A. Janowsky,et al.  Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function , 2013, Psychopharmacology.

[17]  D. Horton,et al.  A translational pharmacology approach to understanding the predictive value of abuse potential assessments , 2013, Behavioural pharmacology.

[18]  Olof Beck,et al.  Multicomponent LC-MS/MS screening method for detection of new psychoactive drugs, legal highs, in urine-experience from the Swedish population. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[19]  A. Kjellgren,et al.  Heaven and Hell—A Phenomenological Study of Recreational Use of 4-HO-MET in Sweden , 2011, Journal of psychoactive drugs.

[20]  A. Janowsky,et al.  Abuse Liability Profile of Three Substituted Tryptamines , 2011, Journal of Pharmacology and Experimental Therapeutics.

[21]  R. Griffiths,et al.  Principles of laboratory assessment of drug abuse liability and implications for clinical development. , 2009, Drug and alcohol dependence.

[22]  M. Forster,et al.  Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats , 2009, Psychopharmacology.

[23]  G. Guzmán Hallucinogenic Mushrooms in Mexico: An Overview , 2008, Economic Botany.

[24]  R. de la Torre,et al.  Liquid chromatography-atmospheric pressure ionization electrospray mass spectrometry determination of "hallucinogenic designer drugs" in urine of consumers. , 2008, Journal of pharmaceutical and biomedical analysis.

[25]  K. Murnane,et al.  The behavioral pharmacology of hallucinogens. , 2008, Biochemical pharmacology.

[26]  Fabrizio Schifano,et al.  Drugs on the web; the Psychonaut 2002 EU project , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[27]  V. Watts,et al.  Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. , 2000, Journal of medicinal chemistry.

[28]  J. C. Winter,et al.  A comparison of N,N-dimethyltryptamine, harmaline, and selected congeners in rats trained with LSD as a discriminative stimulus , 1998, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[29]  Alexander T. Shulgin,et al.  Tihkal : The Continuation , 1997 .

[30]  S. Peroutka,et al.  Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes , 1990, Neuropharmacology.

[31]  K. Mellanby Heaven and Hell , 1978, Nature.

[32]  R. Mowbray,et al.  HALLUCINOGENS , 1970, The Medical journal of Australia.

[33]  S. L. Sherwood Lysergic acid. , 1958, Medical world.